当前位置： SCI文献检索 > JOURNAL OF HYPERTENSION期刊下所有文献 > Impact of the European and American guidelines on hypertension prevalence, treatment, and cardiometabolic goals.

Impact of the European and American guidelines on hypertension prevalence, treatment, and cardiometabolic goals.

Abstract：

OBJECTIVES:Unlike the 2018 European Society of Cardiology/European Society of Hypertension (ESC/ESH) guideline, the 2017 American College of Cardiology/American Heart Association (ACC/AHA) guideline has recommended a shift in hypertension definition from blood pressure (BP) 140/90-130/80 mmHg. Further, they proposed somewhat different indications for antihypertensive medication. No data are available on the comprehensive impact of these guidelines in European countries, where physicians do not always follow guidelines from their own continent. We estimated the prevalence of hypertension, recommendations for antihypertensive medication, and cardiometabolic goals achieved in Spain using the ESC/ESH versus ACC/AHA guidelines. METHODS:We analyzed data from a national survey on 12074 individuals representative of the population aged at least 18 years in Spain. BP was measured with standardized procedures. RESULTS:According to the ESC/ESH and ACC/AHA guidelines, hypertension prevalence was 33.1% (95% confidence interval: 32.2-33.9%) and 46.9% (46.0-47.8%), respectively, and antihypertensive medication was recommended for 33.5% (32.7-34.3%) and 37.2% (36.3-38.1%) of adults, respectively. This represents 5.3 more million hypertensive patients and 1.4 more million candidates for medication (for a 40-million-adults' country) using the ACC/AHA versus the ESC/ESH guideline. Participants who were hypertensive under the ACC/AHA but not the ESC/ESH guideline achieved less frequently some cardiometabolic goals (e.g. nonsmoking, reduced salt consumption, LDL cholesterol if hypercholesterolemic, lifestyle medical advice, and treatment with renin-angiotensin-system blockers where indicated) than those who were hypertensive under the ESC/ESH guideline. CONCLUSION:The implementation of the ACC/AHA versus the ESC/ESH guideline would result in a substantial increase in the prevalence of hypertension and the number of adults who should receive medication. There is room for improvement in lifestyles and cardioprotective treatment in individuals with BP of 130-9/80-9 mmHg whether they are called hypertensive (ACC/AHA) or not (ESC/ESH). We suggest that clinical-practice guidelines should consider the public health and costs implications, and not only the evidence on effectiveness and cost-effectiveness, of their recommendations.

journal_name

J Hypertens

journal_title

Journal of hypertension

authors

Gijón-Conde T,Sánchez-Martínez M,Graciani A,Cruz JJ,López-García E,Ortolá R,Rodríguez-Artalejo F,Banegas JR

doi

10.1097/HJH.0000000000002065

subject

Has Abstract

pub_date

2019-07-01 00:00:00

pages

1393-1400

issue

eissn

0263-6352

issn

1473-5598

pii

00004872-201907000-00012

journal_volume

pub_type

杂志文章

在线工具

Impact of the European and American guidelines on hypertension prevalence, treatment, and cardiometabolic goals.